HERON THERAPEUTICS, INC. /DE/ Quarterly Liabilities and Equity in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Heron Therapeutics, Inc. /De/ quarterly Liabilities and Equity history and growth rate from Q4 2010 to Q3 2024.
  • Heron Therapeutics, Inc. /De/ Liabilities and Equity for the quarter ending September 30, 2024 was $221M, a 3.68% decline year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $221M -$8.42M -3.68% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $218M +$16.9M +8.41% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $218M -$2.99M -1.35% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $223M -$28.4M -11.3% Dec 31, 2023 10-Q 2024-11-12
Q3 2023 $229M -$42.8M -15.7% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $201M -$42.7M -17.5% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $221M -$52.8M -19.3% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $251M -$54.8M -17.9% Dec 31, 2022 10-K 2024-03-12
Q3 2022 $272M -$80.4M -22.8% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $244M -$160M -39.7% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $274M -$37.2M -12% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $306M -$47.9M -13.5% Dec 31, 2021 10-K 2023-03-29
Q3 2021 $352M -$37.6M -9.65% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $404M -$28.5M -6.58% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $311M -$168M -35.1% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 $354M -$159M -31.1% Dec 31, 2020 10-K 2022-02-28
Q3 2020 $390M -$2.94M -0.75% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $433M +$21.1M +5.12% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $479M +$43.1M +9.9% Mar 31, 2020 10-Q 2020-05-06
Q4 2019 $513M +$50.6M +10.9% Dec 31, 2019 10-K 2021-02-24
Q3 2019 $393M -$77.9M -16.6% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $412M -$98.9M -19.4% Jun 30, 2019 10-Q 2019-08-05
Q1 2019 $436M +$252M +138% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 $462M +$228M +97.3% Dec 31, 2018 10-K 2020-03-02
Q3 2018 $471M +$353M +298% Sep 30, 2018 10-Q 2018-11-07
Q2 2018 $511M +$368M +259% Jun 30, 2018 10-Q 2018-08-08
Q1 2018 $183M -$6.18M -3.26% Mar 31, 2018 10-Q 2018-05-10
Q4 2017 $234M +$167M +247% Dec 31, 2017 10-K 2019-02-22
Q3 2017 $118M +$19.4M +19.6% Sep 30, 2017 10-Q 2017-11-06
Q2 2017 $142M +$56.6M +66.1% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $190M +$77.7M +69.5% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $67.5M -$70.4M -51% Dec 31, 2016 10-K 2018-02-27
Q3 2016 $98.8M -$59.3M -37.5% Sep 30, 2016 10-Q 2016-11-08
Q2 2016 $85.7M -$90.7M -51.4% Jun 30, 2016 10-Q 2016-08-08
Q1 2016 $112M +$52.2M +87.6% Mar 31, 2016 10-Q 2016-05-05
Q4 2015 $138M +$61.2M +79.8% Dec 31, 2015 10-K 2017-02-23
Q3 2015 $158M +$65.9M +71.4% Sep 30, 2015 10-Q 2015-11-06
Q2 2015 $176M +$67.8M +62.4% Jun 30, 2015 10-Q 2015-08-07
Q1 2015 $59.6M -$3.17M -5.04% Mar 31, 2015 10-Q 2015-05-08
Q4 2014 $76.7M +$745K +0.98% Dec 31, 2014 10-K 2016-02-19
Q3 2014 $92.3M +$65.9M +250% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 $109M +$70.5M +185% Jun 30, 2014 10-Q 2014-08-04
Q1 2014 $62.8M +$13.8M +28.2% Mar 31, 2014 10-Q 2014-05-12
Q4 2013 $75.9M +$20M +35.7% Dec 31, 2013 10-K 2015-03-13
Q3 2013 $26.4M -$35.4M -57.3% Sep 30, 2013 10-Q 2013-11-12
Q2 2013 $38.1M +$23.9M +168% Jun 30, 2013 10-Q 2013-08-08
Q1 2013 $49M +$34M +227% Mar 31, 2013 10-Q 2013-05-10
Q4 2012 $56M +$36.5M +188% Dec 31, 2012 10-K 2014-03-07
Q3 2012 $61.8M +$40M +183% Sep 30, 2012 10-Q 2012-11-05
Q2 2012 $14.2M -$7.89M -35.7% Jun 30, 2012 10-Q 2012-08-09
Q1 2012 $15M Mar 31, 2012 10-Q 2012-05-10
Q4 2011 $19.4M +$16.5M +568% Dec 31, 2011 10-K 2013-03-01
Q3 2011 $21.8M Sep 30, 2011 10-Q 2011-11-07
Q2 2011 $22.1M Jun 30, 2011 10-Q 2011-08-08
Q4 2010 $2.91M Dec 31, 2010 10-K 2012-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.